Sutimlimab rapidly inhibits classical CP activity and subsequent haemolysis, which coincides with rapid, sustained improvements in fatigue symptoms and overall health-related QOL, further supporting the effectiveness of targeting upstream CP components in the management of patients with CAD. The gene discussed is CP; the disease is cold agglutinin disease.